Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 601–700 of 1,008
Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
Collins, H. M., & Greenfield, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116222 · Cited by 21
“Studies such as these have led to drugs such as Lecanemab and Donanemab (monoclonal antibodies against A β ), which show some efficacy in reducing plaque burden in patients [3,4].”
BackgroundEngineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 13
“Donanemab is also under development to treat AD [38], and cinpanemab is under clinical testing for PD [39]; its development is halted by the FDA [40] likely due to a lack of proof of efficacy [41].”
BackgroundEngels, N., Riphagen, J. M., Egroo, M. V., Koops, E. A., Smegal, L. F., Becker, J. A., Prokopiou, P. C., Bueichekú, E., Kwong, K. K., Rentz, D. M., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27022 · Cited by 20
“1,2 Removing or halting the formation of A β plaques, typically detected as fi brillar A β by positron emission tomography (PET), may occur too late in the disease or be insuf fi - cient to mitigate A β ’ s detrimental effects on tau proliferation and cognitive decline.”
Donanemab eligibility in early Alzheimer's disease: A real-world study
Urso, D., Introna, A., Gnoni, V., Giugno, A., Vilella, D., Zecca, C., Blasi, R. D., Giannoni‐Luza, S., & Logroscino, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331243 · Cited by 16
“However, several critical concerns remain, 4 including the high screening failure rates in these trials, approaching 80%, 2,3 which raises questions about the generalizability of the fi ndings to real-world clinical settings.”
The Development of Pharmacological Therapies for Alzheimer’s Disease
Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 17
The Role of Immunity in Alzheimer's Disease
McManus, R. M. (2022) · Advanced Biology · doi:10.1002/adbi.202101166 · Cited by 18
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 20
“Furthermore, monoclonal antibody therapies are now available that can remove Aβ plaques and can slow cognitive, functional and clinical decline when used in the early clinical stages of AD 13,14 .”
Gaire, B. P., Koronyo, Y., Vit, J., Hutton, A., Subedi, L., Fuchs, D.-T. S., Swerdlow, N., Rentsendorj, A., Shahin, S., Martinon, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68580-4 · Cited by 20
Engineering chimeric antigen receptor CD4 T cells for Alzheimer’s disease
Boskovic, P., Shalita, R., Gao, W., Vernon, H., Deng, Y. L., Colonna, M., Majzner, R. G., Amit, I., & Kipnis, J. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2530977123 · Cited by 20
Wojtunik‐Kulesza, K. A., Oniszczuk, T., Mołdoch, J., Kowalska, I., Szponar, J., & Oniszczuk, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031212 · Cited by 16
“Information obtained from the studies indicates that the optimal therapeutic window might be before the onset of appreciable Aβ plaque deposition; hence, the solution can be used in preventive therapy [39].”
BackgroundWang, S., Zheng, K., Kong, W., Huang, R., Liu, L., Wen, G., & Yu, Y. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac515 · Cited by 16
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 17
Lyu, D., Lyu, X., Huang, L. T., & Fang, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101959 · Cited by 15
ten Kate, M., Barkhof, F., & Schwarz, A. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.92 · Cited by 15
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
Shcherbinin, S., Morris, A., Higgins, I. A., Tunali, I., Lu, M., Deveau, C., Southekal, S. S., Kotari, V., Evans, C. D., Arora, A., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12415 · Cited by 18
“16,19 In TB, only participants with low/medium-tau (described below) assessed by flortaucipir PET subsequently completed a florbetapir scan.”
MethodSelf-citationThe several ways to authentically cure Alzheimer’s dementia
Fessel, J. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102093 · Cited by 15
Buchholz, A. S., Deme, P., Betz, J., Brandt, J., Haughey, N. J., & Cervenka, M. C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1182519 · Cited by 24
Aerobic Exercise Training for the Aging Brain: Effective Dosing and Vascular Mechanism
Tarumi, T., Tomoto, T., Sugawara, J., & Zhang, R. (2024) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000349 · Cited by 23
Aliaga, A., Therriault, J., Quispialaya, K. M., Aliaga, A., Hopewell, R., Rahmouni, N., Macedo, A. C., Kunach, P., Soucy, J., Massarweh, G., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267539 · Cited by 19
“Tau PET is increasingly used as a secondary outcome measure in disease-modifying clinical trials ( 29 – 31 ).”
Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
Boada, M., Martínez‐Lage, P., Serrano-Castro, P. J., Costa, M., & Páez, A. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1960823 · Cited by 16
Precision Medicine and Distributive Justice: Wicked Problems for Democratic Deliberation
Fleck, L. M. (2022) · doi:10.1093/oso/9780197647721.001.0001 · Cited by 17
Gregory, S., Saunders, S., & Ritchie, C. W. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00219-7 · Cited by 18
“However, treated patients had decreased plasma and CSF total amyloid β 40 and amyloid β 42 compared with untreated patients in the solanezumab trial, although, as these were secondary outcomes analysed in the context of a non-significant primary analysis, these results were not considered to be…”
ResultFDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Alavi, A. A., & Barrio, J. R. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004710 · Cited by 16
Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
“Secreted pro-neurotrophins are processed by extracellular matrix proteases to produce the mature forms in a regulated cascade-like manner, as exemplified for pro-NGF [80].”
BackgroundTherapeutic news in Alzheimer’s disease: Soon a disease-modifying therapy?
Villain, N. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.02.456 · Cited by 14
“In addition, two other anti-amyloid antibodies responsible for high clearance of amyloid deposits have shown positive phase II trials results on clinical endpoints: lecanemab and donanemab [20,21].”
Background2021 marks a new era for Alzheimer's therapeutics
Kantarci, K. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00412-9 · Cited by 14
Aducanumab: What about the Patient?
Petersen, R. C. (2021) · Annals of Neurology · doi:10.1002/ana.26181 · Cited by 14
“This person, after hearing the discussion of the rationale for lowering the level of amyloid in the brain and the uncertain clinical benefit in the setting of the potential side effects of amyloid-related imaging abnormalities (ARIA), deserves the opportunity to participate in the decision.(4) Although the ARIA can be…”
BackgroundForlenza, O. V., & Barbosa, B. J. A. P. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-e001 · Cited by 22
Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
Siebrand, C. J., Bergo, N. J., Lee, S., Andersen, J. K., & Walton, C. C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06572-6 · Cited by 15
“These antibodies are specifically designed to target insoluble Aβp3-42-rich plaques, particularly core plaques deposited in the brain parenchyma, while avoiding soluble Aβ species [1, 43, 44].”
Kjærgaard, D., Nielsen, T. R., Stomrud, E., Palmqvist, S., Bali, D., Dolado, A. O., Janelidze, S., Hansson, O., Waldemar, G., & Simonsen, A. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70315 · Cited by 19
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 19
Immunity in Alzheimer’s disease: From mechanisms to therapies
Chen, X., Holtzman, D. M., & Colonna, M. (2026) · Immunity · doi:10.1016/j.immuni.2026.02.004 · Cited by 23
Jiang, Y., Zheng, W., Xia, Z., Wong, W. W., Cheng, L. K., Ip, F. C. F., Choi, S. M., Chan, A. L., Lam, C. Y., Ho, K. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536792123 · Cited by 19
Lou, C., Habes, M., Illenberger, N., Ezzati, A., Lipton, R. B., Shaw, P. A., Stephens‐Shields, A. J., Akbari, H., Doshi, J. J., Davatzikos, C. A., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab264 · Cited by 15
“23 Though many modern clinical trials of neurologic disease now incorporate baseline MR imaging into their protocol, 24–30 especially in those of Alzheimer’s disease and GBM, which we use as examples in this manuscript, imaging remains expensive and potentially extraneous for the study of certain…”
Gauthier, S. G., Boxer, A. L., Knopman, D. S., Sims, J., Doody, R. S., Aisen, P., Iwatsubo, T., Bateman, R. J., & Vellas, B. J. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.29 · Cited by 14
“aducanumab phase 3, and lecanemab and donanemab phase 2 trials) was relatively small and consisted of a reduction in the rate of clinical worsening (8).”
BackgroundSelf-citationHabashi, M., Chauhan, P. S., Vutla, S., Senapati, S., Diachkov, M., El‐Husseini, A., Guérin, B., Lubell, W. D., & Rahimipour, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02049 · Cited by 18
Filippi, M., Cecchetti, G., Cagnin, A., Marra, C., Nobili, F. M., Parnetti, L., & Agosta, F. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11642-0 · Cited by 15
Convexity subarachnoid haemorrhage: a practical guide
Ly, J. V., Ma, H., Singhal, S., Clissold, B. G., & Phan, T. G. (2023) · Practical Neurology · doi:10.1136/pn-2022-003572 · Cited by 17
Danziger, R., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Sheyn, J., Hayden, E. Y., Teplow, D. B., Black, K. L., Fuchs, S., Bernstein, K. E., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1179315 · Cited by 16
“Given the injurious role that soluble Aβ42 oligomers play in AD pathophysiology, there has been considerable effort to target and remove them as a strategy to prevent disease progression (Viola and Klein, 2015; Honig et al., 2018; Alexander et al., 2021; Mintun et al., 2021).”
BackgroundMRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease
Filippi, M., Cecchetti, G., & Agosta, F. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001177 · Cited by 14
“7%) [3,26], whereas a lower rate of ARIA-E was detected in lecanemab Clarity Alzheimer’s disease phase-3 trial (12.”
BackgroundUpdates on pharmacological treatment for Alzheimer’s disease
Tipton, P. W. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 17
Weiner, S., Blennow, K., Zetterberg, H., & Gobom, J. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2255752 · Cited by 16
Geroscience and Alzheimer's Disease Drug Development
Cummings, J. L., Osse, A. M. L., & Kinney, J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.103 · Cited by 16
Ramírez, S., Koerich, S., Astudillo, N., Gregorio, N. D., Al‐Lahham, R., Allison, T., Rocha, N. P., Wang, F., & Soto, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317087 · Cited by 14
A case for seeking sex-specific treatments in Alzheimer’s disease
Lynch, M. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1346621 · Cited by 20
Clinical classification of memory and cognitive impairment with multimodal digital biomarkers
Banks, R., Higgins, C., Greene, B. R., Jannati, A., Gomes‐Osman, J., Tobyne, S. M., Bates, D. W., & Pascual‐Leone, Á. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12557 · Cited by 14
Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories
Jang, H., Chun, M. Y., Yun, J., Kim, J. P., Kang, S. H., Weiner, M. W., Kim, H. J., Na, D. L., Hong, C., Son, S. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14247 · Cited by 15
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 18
“Ultimately, TRAILBLAZER-ALZ1 showed that donanemab led to a modest reduction in cognitive and functional decline, but the study’s ultimate goal of slowing disease progression by half was not achieved [32].”
BackgroundViña, J., Borrás, C., & Mas‐Bargues, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240308 · Cited by 16
Molecular mechanisms of sulforaphane in Alzheimer’s disease: insights from an in-silico study
Vu, G. H., & Nguyen, H. D. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00267-4 · Cited by 16
“…antibodies like aducanumab and leqembi, these drugs cannot cure AD and cause side effects (e.g., brain swelling, microbleeds, fatigue, nausea, etc.), and a significant proportion of individuals in developing nations lack access to these interventions (Mintun et al. 2021; Salloway et al. 2022).”
BackgroundChang, Y. Z., Liu, J., Xu, X., Sun, S., Zhang, J., Zhang, X., Lu, G., Xiao, S., Cao, Y., Wu, R., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07016-x · Cited by 15
“…assessment is especially pertinent in MCI stage that is an optimal phase for assessing the efficacy of disease-modifying interven - tions [56, 57] For amyloid-targeted treatments, establishing prognostic factors for Aβ-positive MCI patients could pro - vide a crucial risk stratification…”
Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2025) · Journal of Medical Internet Research · doi:10.2196/68454 · Cited by 20
“The APOE - ε 4 allele dose (homozygotes > heterozygotes) is the strongest risk factor for ARIA development, treatment discontinuation, and symptom manifestation, likely due to increased vascular A β burden and reduced cerebrovascular integrity [16,23,72,87,93].”
InfluentialCuberas‐Borrós, G., Roca, I., Castell‐Conesa, J., Núñez, L., Boada, M., López, O. L., Grifols, C., Barceló, M., Pareto, D., & Páez, A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05915-5 · Cited by 14
A patent review of glutaminyl cyclase inhibitors (2004–present)
Coimbra, J. R. M., & Salvador, J. A. R. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1917549 · Cited by 16
McLaughlin, J., Scotton, W. J., Ryan, N. S., Hardy, J. A., & Shoai, M. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14314 · Cited by 11
Serum/glucocorticoid regulated kinase 1 (SGK1) in neurological disorders: pain or gain
Howard, P. G., Zou, P., Zhang, Y., Huang, F., Tesic, V., Wu, C. Y.-C., & Lee, R. H.-C. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114973 · Cited by 13
Kang, Y.-K., Min, J. W., Kwon, S. J., & Ha, S. (2025) · Tomography · doi:10.3390/tomography11080086 · Cited by 15
“Particularly, the donanemab trial set a Centiloid threshold of 37 for eligibility and defined treatment discontinuation criteria based on Centiloid value reductions [14,15], indicating its potential pivotal roles in the era of amyloid-targeting drugs.”
Sex Differences in P-Tau217, Tau Aggregation, and Cognitive Decline
Coughlan, G., Ourry, V., Townsend, D. L., Klinger, H. M., Brown, J. A., Cuppels, M., Betthauser, T. J., Langhough, R. E., Cody, K. A., Seto, M., et al. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2025.5670 · Cited by 16
Self-citationCullen, N. C., Janelidze, S., Stomrud, E., Bateman, R. J., Palmqvist, S., Hansson, O., & Mattsson, N. (2023) · Brain Communications · doi:10.1093/braincomms/fcad015 · Cited by 14
Wang, Z., Jin, M., Hong, W., Liu, W., Reczek, D., Lagomarsino, V. N., Hu, Y., Weeden, T., Frosch, M. P., Young‐Pearse, T. L., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01511-2 · Cited by 16
“Since completion of our experiments a phase 2 trial of an antibody specific for N-terminal pyro-glutamate-3 Aβ (pE3-Aβ), donanemab, has yielded encouraging results in patients with early Alzheimer’s disease [30].”
ResultHao, Y., Dong, M., Sun, Y., Duan, X., & Niu, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1147757 · Cited by 13
Dranitsaris, G., Zhang, Q., Mu, L., Weyrer, C., Drysdale, E., Neumann, P. J., Atri, A., & Monfared, A. A. T. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01207-8 · Cited by 15
Samuels, J. D., Lukens, J. R., & Price, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15981 · Cited by 23
“…designed to promote A β uptake by immune cells and clearance from the brain have reached clinical trials, including Aducanumab (Tampi et al., 2021 ), Gantenerumab (Bateman et al., 2022 ), Lecanemab (van Dyck et al., 2023 ), and Do-nanemab (Gueorguieva et al., 2023; Mintun et al., 2021 ).”
Wang, G., Li, Y., Xiong, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J. J., Aschenbrenner, A. J., McDade, E., Clifford, D. B., Libre‐Guerra, J. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13735 · Cited by 11
Caring for Individuals with Alzheimer’s Disease: A Spotlight on Hispanic Caregivers
Garcia, R. I., Khemka, S., Roghani, A. K., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, A. P., Sehar, U., & Reddy, P. H. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240035 · Cited by 13
Zhou, J., Wang, N., Wang, M., Hu, Y., Zhang, Z., Gu, Z., Wang, J., Shou, H., Cheng, X., Liu, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00159 · Cited by 14
Chandler, J., Ye, W., Mi, X., Doty, E. G., & Johnston, J. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231166 · Cited by 18
Spatial extent as a sensitive amyloid‐PET metric in preclinical Alzheimer's disease
Farrell, M. E., Thibault, E. G., Becker, J. A., Price, J. C., Healy, B. C., Hanseeuw, B. J., Buckley, R. F., Jacobs, H. I. L., Schultz, A. P., Chen, C. D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14036 · Cited by 16
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 16
“Although a phase II clinical trial in 2021 (TRAILBLAZER-ALZ, clinicaltrials.gov NCT03367403) showed a reduction in Aβ levels compared to placebo, no significant reduction in cognitive and functional impairment was observed [15].”
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 18
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Høilund‐Carlsen, P. F., Alavi, A. A., & Barrio, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240206 · Cited by 13
Stem cell therapy in Alzheimer’s disease: current status and perspectives
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440334 · Cited by 19
“Despite being approved, however, research on potentially severe brain hemorrhage and swelling is still lacking (Couzin-Frankel, 2023; Honig et al., 2018; Mintun et al., 2021; van Dyck et al., 2023).”
The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)
Mormino, E. C., Biber, S., Rahman‐Filipiak, A., Arfanakis, K., Clark, L. R., Dage, J. L., Detre, J. A., Dickerson, B. C., Donohue, M., Kecskemeti, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14383 · Cited by 18
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 22
“ARIA-E was reported in 6.1% of participants [141, 207, 208].”
InfluentialDonanemab exposure‐response in early symptomatic Alzheimer's disease
Gueorguieva, I., Chow, K. H., Chua, L., Shcherbinin, S., Zimmer, J. A., Evans, C. D., Wang, H., Nery, E. S. M., Brooks, D. A., & Sims, J. R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70491 · Cited by 17
Self-citationGandy, S., Knopman, D. S., & Sano, M. C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00490-z · Cited by 16
“Published phase 2 data from donanemab showed ~ 33% slowing of cognitive decline on a prespecified endpoint [7].”
MethodBenninghoff, J., & Perneczky, R. (2022) · Springer eBooks · doi:10.1007/978-3-319-56015-1_195-1 · Cited by 26
Teng, E., Li, Y., Manser, P. T., Pickthorn, K., Butcher, B. D., Blendstrup, M., RANDOLPH, C. C., & Sikkes, S. A. M. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12452 · Cited by 16
Matsumoto, H., Tagai, K., Endo, H., Matsuoka, K., Takado, Y., Kokubo, N., Shimada, H., Goto, T., Goto, T. K., & Higuchi, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230581 · Cited by 15
Vellas, B. J. (2021) · The journal of nutrition health & aging · doi:10.1007/s12603-021-1657-8 · Cited by 14
Hermann, D. M., Bacigaluppi, M., Bassetti, C. L., Bassotti, G., Boltze, J., Chan, A., Dalkara, T., Denes, A., Diez-Tejedor, E., Dodel, R., et al. (2025) · Exploration of Neuroscience · doi:10.37349/en.2025.1006106 · Cited by 13
“In Alzheimer’s disease, a devastating neurodegenerative condition, immune therapies targeting β -amyloid (A β ) have recently been found to slow down cognitive decline and enhance daily life activities, although still to a moderate extent [6, 7].”
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13
Yan, L., Zhang, L., Xu, Z., & Luo, Z. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1559447 · Cited by 15
Brüge, A., Ponimaskin, E. G., & Labus, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100071 · Cited by 14
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
“310 Similarly, the phase 3 TRAILBLAZER-ALZ 2 trial showed that donanemab reduced clinical decline by 35% at 76 weeks and lowered the decline in daily living abilities by 40% compared to placebo in individuals with early symptomatic AD.”
Adaptive immunity in the neuroinflammation of Alzheimer’s disease
Liu, H., Chen, Y., Zhang, J., & Chen, X. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003695 · Cited by 15
“[140,141] The treatment has ushered in a new era of disease-modifying therapies.”
Kopeć, K., Koziorowski, D., & Szlufik, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157552 · Cited by 16
“Research has demonstrated that Donanemab and Lecanemab are effective in reducing amyloid levels in the brain and moderately slowing down cognitive decline [33,34].”
Mir, P. A., Kumar, N. G., Bhutia, G. T., Chaudhary, P., Kaur, G., & Gupta, S. K. (2026) · GeroScience · doi:10.1007/s11357-025-02062-1 · Cited by 15
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J. L., Aisen, P. S. S., Lemere, C. A., Atri, A., Sabbagh, M. N., & Salloway, S. (2021) · Aktualności Neurologiczne · doi:10.15557/an.2021.0014 · Cited by 12
Self-citationMethods for the isolation and analysis of Aβ from postmortem brain
Hong, W., Liu, W., DeSousa, A., Young‐Pearse, T. L., & Walsh, D. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1108715 · Cited by 13
“, lecanemab, aducanumab, and donanemab) which facilitate the removal of amyloid plaques can slow cognitive decline in mild AD patients (Sevigny et al., 2017; Mintun et al., 2021; Swanson et al., 2021a,b; Budd Haeberlein et al., 2022; van Dyck et al., 2022).”
BackgroundWang, B., Shi, J.-Z., Guo, N., Shao, L., Zhai, W., Jiang, L., Zhao, F., Wang, J., Wang, J., Du, L.-D., et al. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341900 · Cited by 13
Volloch, V., & Rits‐Volloch, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417586 · Cited by 13
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s
Salvadó, G., Horie, K., Barthélemy, N. R., Vogel, J. W., Binette, A. P., Chen, C. D., Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.075367 · Cited by 14
Song, Y., Dai, C., Shinohara, M., Tung, Y. C., Zhou, S., Huang, W., Seffouh, A., Luo, Y., Willadsen, M., Jiao, Y., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.028 · Cited by 15
Benetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 15
Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenigro, P. H., Siemers, E., Sink, K. M., Shaw, L. M. J., Hansen, C. T., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70013 · Cited by 19
“This revision aimed to incorporate recent advances in treatments 6–9 and biomarker development, 10–12 as well as a shift in the scientific community to define AD biologically rather than based on its syndromic presentation.”
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 16
“…at risk of memory loss III [197,198] Gantenerumab Mild AD, prodromal to mild AD, early AD III [123,199,200] Aducanumab Early AD III [201–203] Crenezumab Prodromal to mild AD III [204] Lecanemab Early AD, preclinical AD III [205] Donanemab Early symptomatic AD, preclinical AD III [206] 4.1.1.”
InfluentialRecent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 19
“Tau hyperphosphorylation reduces its stability and affinity for microtubules, resulting in microtubule disintegration, self-aggregation of separated molecules, misfolding into tau oligomers, and aggregation into neurofibrillary tangles.”
Sabbagh, M. N., Zhao, C., Mahendran, M., Jang, S. R., Laliberté, F., Toyosaki, H., Zhang, K., Frech, F. H., & Nair, K. V. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00756-4 · Cited by 14
“These novel treatments target the underlying pathogenesis of AD and have shown the ability to slow clinical decline in affected patients [13, 14].”
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.